Cargando…
Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218317/ https://www.ncbi.nlm.nih.gov/pubmed/34188921 http://dx.doi.org/10.1002/ccr3.4227 |